Clinical Trial Update: Open Label Extension to Bridging Study CTBM100C2303 [Phase 3]

View source ↗

Summary

Open-label extension to a bridging Phase 3 study for Pseudomonas aeruginosa and cystic fibrosis was completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pseudomonas Aeruginosa Infection

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pseudomonas Aeruginosa, Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2021-06-02